Tolerance and Efficacy of Omniscan (Gadodiamide Injection) in MR Imaging of the Central Nervous System

Abstract

Purpose:

This Swedish multicenter trial was performed on patients with known or suspected lesions of the CNS for which an MR examination using a contrast medium was indicated. A total of 8 MR centers participated in the study to establish the safety and efficacy of Omniscan (gadodiamide injection) in clinical routine using a standard dose of 0.1 mmol Gd/kg b.w.

Material and Methods:

Seven hundred adult patients who had been referred for MR investigation of suspected CNS lesions were included in the study. Since most patients were examined on an outpatient basis, it was decided to use an explicit questionnaire regarding adverse events that developed within 24 h after examination. The efficacy evaluation involved comparisons of detectability, delineation, and number of lesions before and after injection of Omniscan.

Results:

No serious or unexpected adverse event was found. There were a total of 70 (10.2%) patients with adverse events, excluding those judged not to be contrast media-related. However, only 15 patients (2.2%) had adverse events that possibly or probably were related to the contrast medium. Usually, the symptoms were headache, dizziness, abnormal taste, and nausea. Two patients complained of itching, but only one developed urticaria. The efficacy was similar to that of other currently used Gd-based MR agents. Lesions were more often seen on T2-weighted images, but the contrast medium improved lesion delineation, contributing to higher certainty in diagnosis, and provided more confidence in excluding suspected abnormality.

Conclusion:

Omniscan was found to be a safe and clinically valuable contrast medium for MR imaging of the CNS.

Keywords

Central nervous system contrast medium safety efficacy gadodiamide injection

Get full access to this article

View all access options for this article.

References

Aslanian

Lemaignen

Bonoof

Svaland

Børseth

Lundby

: Evaluation of the clinical safety of gadodiamide injection (Omniscan), a new non-ionic MR contrast agent for the central nervous system. A European perspective. Neuroradiology (1995).

Baleriaux

Matos

De Greef

: Gadodiamide injection as a contrast medium for MRI of the central nervous system. A comparison with gadolinium-DOTA. Neuroradiology 35 (1993), 490.

Brugières

Gaston

Degryse

H. R.

: Randomized double blind trial of the safety and efficacy of two gadolinium complexes (Gd-DTPA and Gd-DOTA). Neuroradiology 36 (1994), 27.

Myhr

Rinck

P. A.

Børseth

: Gadodiamide injection and gadopentetate dimeglumine. A double blind study in MR imaging of the CNS. Acta Radiol. 33 (1992), 405.

Nycomed Imaging A/S, Oslo, Norway: Personal communication (1994).

Sze

Brant-Zawadzki

Haughton

V. M.

: Multicenter study of gadodiamide injection as a contrast agent in MR imaging of the brain and spine. Radiology 181 (1991), 693.

Valk

Algra

P. R.

Hazenberg

C. J.

Slooff

W. B. M.

Svaland

M. G.

: A double blind, comparative study of gadodiamide injection and gadopentetate dimeglumine in MR examinations of the central nervous system. Neuroradiology 35 (1993), 173.